bd 4

Mtb-cyt-bd oxidase-IN-4, an inhibitor of Mycobacterium tuberculosis cytochrome bd oxidase (Mtb cyt-bd oxidase), demonstrates potent activity with an IC50 value of 0.25 μM and inhibits the growth of Mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) of 8 μM. This compound is utilized in tuberculosis research.

ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with nanomolar binding affinities to the bromodomains (BDs) of BRD4, exhibiting IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

BD 1008 Free Base is a selective sigma receptor antagonist, with a reported binding affinity of Kᵢ = 2 ± 1 nM for the sigma-1 receptor and 4 times selectivity over the sigma-2 receptor.

Mtb-cyt-bd oxidase-IN-6, a potent inhibitor of Mycobacterium tuberculosis (Mtb) cytochrome bd (cyt-bd) oxidase (MtbCyt-bd Oxidase), exhibits an inhibitory concentration (IC50) of 0.35 μM and effectively suppresses Mtb growth with a minimum inhibitory concentration (MIC) of 4 μM. This compound is utilized in tuberculosis research [1].